Do you have adult patients in your practice with Congenital Adrenal Hyperplasia (CAH)?
Most require high-dose prednisone or cortisol replacement therapy, and suffer the long term consequences of that treatment as well as persistent overproduction of androgens and other steroids.
A new oral medication for CAH, Tildacerfont, acts at the level of the pituitary to reduce the production of unwanted androgens and other steroids, and enables a lower dose of prednisone or cortisol replacement to be used. It is currently being studied in two different multi-centre clinical trials at the Health Sciences Centre. The local principal investigator is the endocrinologist, Dr. Christopher Kovacs.
If you have patients with CAH who may be interested in trying this new treatment in the form of a clinical trial, please have them contact the research nurse coordinator, Krista Cuff, at 777-6996 or by email: [email protected].